Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Oct;79(10):1303-1314.
doi: 10.1007/s00228-023-03542-z. Epub 2023 Aug 14.

Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis

Dan Zhang  1 , Yasi Xu  2 , Xiang Wang  1 , Leping Hou  1 , Mengyu Xing  1 , Shuang Xu  1 , Rui Guo  1 , Ying Luo  3
Affiliations
Meta-Analysis

Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis

Dan Zhang et al. Eur J Clin Pharmacol. 2023 Oct.

Abstract

Purpose: The incidence of linezolid-induced thrombocytopenia (LIT) has been reported to vary widely across studies. We performed a meta-analysis to identify the risk factors for thrombocytopenia among patients who received linezolid treatment.

Methods: The PubMed, Embase and Cochrane Library databases were searched from inception to November 2022 to identify eligible studies. Data on the potential predictors of incidence in LIT were pooled using a random effects model. Sensitivity analyses were performed to determine the robustness of the results when significant heterogeneity was observed.

Results: Forty observational studies involving 6454 patients treated with linezolid were included in the analysis. LIT was estimated to occur in 37% of patients. The following important factors were associated with the incidence of LIT: advanced age, body mass index, concurrent renal impairment or liver disease, abnormal laboratory parameters (including white blood cell count, serum creatinine, baseline platelet count, albumin, creatinine clearance rate, and estimated glomerular filtration rate), treatment duration and renal replacement therapy.

Conclusions: A variety of risk factors related to the occurrence of LIT were revealed in our analysis. Early identification of these factors could help patients improve clinical outcomes.

Keywords: Linezolid; Meta-analysis; Risk factors; Systematic review; Thrombocytopenia.

PubMed Disclaimer

References

    1. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R (2001) Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45(6):1843–1846. https://doi.org/10.1128/AAC.45.6.1843-1846.2001 - DOI - PubMed - PMC
    1. Rybak JM, Barber KE, Rybak MJ (2013) Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin Pharmacother 14(14):1919–1932. https://doi.org/10.1517/14656566.2013.820276 - DOI - PubMed
    1. Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42(13):1129–1140. https://doi.org/10.2165/00003088-200342130-00004 - DOI - PubMed
    1. Roger C, Roberts JA, Muller L (2018) Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet 57(5):559–575. https://doi.org/10.1007/s40262-017-0601-x - DOI - PubMed
    1. Cattaneo D, Marriott DJ, Gervasoni C (2023) Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations. Expert Rev Clin Pharmacol 16(3):219–230. https://doi.org/10.1080/17512433.2023.2181160 - DOI - PubMed

LinkOut - more resources